ProACT in the management of stress urinary incontinence after radical prostatectomy. What happens after 8 years of follow up? monocentric analysis in 42 patients.

Q3 Pharmacology, Toxicology and Pharmaceutics
Maida Bada, Felice Crocetto, Biagio Barone, Davide Arcaniolo, Sebastiano Rapisarda, Antonio Aliberti, Guglielmo Zeccolini, Antonio Celia
{"title":"ProACT in the management of stress urinary incontinence after radical prostatectomy. What happens after 8 years of follow up? monocentric analysis in 42 patients.","authors":"Maida Bada,&nbsp;Felice Crocetto,&nbsp;Biagio Barone,&nbsp;Davide Arcaniolo,&nbsp;Sebastiano Rapisarda,&nbsp;Antonio Aliberti,&nbsp;Guglielmo Zeccolini,&nbsp;Antonio Celia","doi":"10.1515/jbcpp-2021-0295","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Stress urinary incontinence is defined by a complaint of any involuntary loss of urine on effort or physical exertion or on sneezing or coughing and represents a major complication after radical prostatectomy. According to surgical technique, incidence of post-prostatectomy incontinence varies from open (7-39.5%), laparoscopic (5-33.3%) or robotic-assisted (4-31%) approaches. The ProACT<sup>®</sup> device (Uromedica, Inc., MN) is a possible surgical option for the treatment of this condition.</p><p><strong>Methods: </strong>We retrospectively analyzed surgical records of consecutive patients underwent ProACT<sup>®</sup> implantation in our department between January 2006 to November 2010. We collected data at 6 and 12 months after surgical approach about the daily pad use, International Prostatic Symptoms Score and its quality of life domain.</p><p><strong>Results: </strong>42 patients were included in the final analysis. Most patients (92.9%) received minimally invasive surgery for treating prostate cancer. During the follow up after 6 and 12 months, the daily pad, International Prostatic Symptom Score and its quality of life domain significantly improved compared to preoperative outcomes. The logistic regression analysis found that presence of comorbidities was the only predictive factor of low satisfaction rate (PGE-I > 2) in patients who underwent ProACT<sup>®</sup> implant.</p><p><strong>Conclusions: </strong>ProACT<sup>®</sup> implant represents an effective and safe treatment for post-prostatectomy stress urinary incontinence with a high satisfaction degree and a low rate of complications.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Physiology and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jbcpp-2021-0295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 2

Abstract

Objectives: Stress urinary incontinence is defined by a complaint of any involuntary loss of urine on effort or physical exertion or on sneezing or coughing and represents a major complication after radical prostatectomy. According to surgical technique, incidence of post-prostatectomy incontinence varies from open (7-39.5%), laparoscopic (5-33.3%) or robotic-assisted (4-31%) approaches. The ProACT® device (Uromedica, Inc., MN) is a possible surgical option for the treatment of this condition.

Methods: We retrospectively analyzed surgical records of consecutive patients underwent ProACT® implantation in our department between January 2006 to November 2010. We collected data at 6 and 12 months after surgical approach about the daily pad use, International Prostatic Symptoms Score and its quality of life domain.

Results: 42 patients were included in the final analysis. Most patients (92.9%) received minimally invasive surgery for treating prostate cancer. During the follow up after 6 and 12 months, the daily pad, International Prostatic Symptom Score and its quality of life domain significantly improved compared to preoperative outcomes. The logistic regression analysis found that presence of comorbidities was the only predictive factor of low satisfaction rate (PGE-I > 2) in patients who underwent ProACT® implant.

Conclusions: ProACT® implant represents an effective and safe treatment for post-prostatectomy stress urinary incontinence with a high satisfaction degree and a low rate of complications.

ProACT在根治性前列腺切除术后应激性尿失禁治疗中的应用。8年的随访后会发生什么?42例患者的单中心分析。
目的:压力性尿失禁被定义为在努力或体力消耗或打喷嚏或咳嗽时出现的非自愿尿失禁,是根治性前列腺切除术后的主要并发症。根据手术技术的不同,前列腺切除术后尿失禁的发生率不同于开放(7-39.5%)、腹腔镜(5-33.3%)或机器人辅助(4-31%)入路。ProACT®设备(Uromedica, Inc., MN)是治疗这种疾病的一种可能的手术选择。方法:回顾性分析2006年1月至2010年11月在我科连续行ProACT®植入术患者的手术记录。我们在手术入路后6个月和12个月收集关于每日尿垫使用、国际前列腺症状评分及其生活质量领域的数据。结果:42例患者纳入最终分析。大多数患者(92.9%)接受微创手术治疗前列腺癌。随访6个月和12个月时,患者每日尿垫、国际前列腺症状评分及其生活质量域较术前有明显改善。logistic回归分析发现,合并症的存在是ProACT®种植体患者满意度低(PGE-I > 2)的唯一预测因素。结论:ProACT®假体治疗前列腺切除术后应激性尿失禁是一种安全有效的治疗方法,满意度高,并发症发生率低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Basic and Clinical Physiology and Pharmacology
Journal of Basic and Clinical Physiology and Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
3.90
自引率
0.00%
发文量
53
期刊介绍: The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信